论文部分内容阅读
目的比较坦索罗辛和非那甾安治疗良性前列腺增生症的临床疗效。方法良性前列腺增生症患者80例,平均年龄64．5岁,随机分为两研究组,两组患者治疗前I-PSS、最大尿流率、剩余尿量和前列腺体积的基线值差异比较无显著性意义,观察记录治疗12周前后I-PSS、最大尿流率、剩余尿量和前列腺体积的变化。结果坦索罗辛组治疗后I-PSS、Qmax和剩余尿最均有明显改善(P＜0．05),非那甾安组治疗后剩余尿量有明显改善(P＜0．05),坦索罗辛组比非那甾安组在改善I-PSS和Qmax方面有显著统计学差异(P＜0．01)。结论坦索罗辛较非那甾安治疗良性前列腺增生症起效快,改善临床症状效果显著,特别是在Qmax和IPSS方面较为明显。
Objective To compare the clinical efficacy of tamsulosin and finasteride in the treatment of benign prostatic hyperplasia. Methods 80 patients with benign prostatic hyperplasia (mean age 64.5 years) were randomly divided into two groups. There was no significant difference in baseline I-PSS, maximal urinary flow rate, residual urine volume and prostate volume between the two groups before treatment The significance of I-PSS, maximal uroflow rate, residual urine volume and prostate volume were observed and recorded before and after treatment for 12 weeks. Results After tamsulosin treatment, the I-PSS, Qmax and remaining urine were all significantly improved (P <0.05), the remaining urine volume was significantly improved after treatment with finasteride (P <0.05) There was a significant difference between tamsulosin group and finasteride in improving I-PSS and Qmax (P <0.01). Conclusion Tamsulosin is more effective than phenazapan in the treatment of benign prostatic hyperplasia, and its clinical effect is remarkable, especially in Qmax and IPSS.